Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone

MT Newswires Live07-27

Pacira BioSciences (PCRX) said Monday that it has enrolled the first patient in part B of its mid-stage trial evaluating PCRX-201, an investigational gene therapy for osteoarthritis of the knee, after successfully transitioning the therapy to a US-based commercial-scale manufacturing process.

Enrollment in Part A concluded last month, with topline data expected by the end of the year, the company said.

Pacira said the manufacturing transition, together with PCRX-201's Regenerative Medicine Advanced Therapy designation and encouraging early-stage results, supports the program's future late-stage development.

The company said the manufacturing change was completed without delaying the ongoing mid-stage trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment